Growth factor receptor-Src-mediated suppression of GRK6 dysregulates CXCR4 signaling and promotes medulloblastoma migration

Molecular Cancer

Volumn 12, Issue 1, 2013, Pages

  Yuan, Liangping ^a   Zhang, Hongying ^a   Liu, Jingbo ^a   Rubin, Joshua B ^b   Cho, Yoon Jae ^c   Shu, Hui Kuo ^a   Schniederjan, Matthew ^a   MacDonald, Tobey J ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CXCR4; GRK6; Growth factor receptor; Medullobastoma; PDGFR; Src

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR KINASE; G PROTEIN COUPLED RECEPTOR KINASE 6; GROWTH FACTOR RECEPTOR; PLERIXAFOR; STEROID RECEPTOR COACTIVATOR 1;

ARTICLE; CELL MIGRATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; LENTIVIRUS INFECTION; MEDULLOBLASTOMA; METASTASIS; MICROARRAY ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RETROVIRUS INFECTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

CELL LINE, TUMOR; CELL MOVEMENT; CEREBELLAR NEOPLASMS; CHEMOKINE CXCL12; G-PROTEIN-COUPLED RECEPTOR KINASES; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HEDGEHOG PROTEINS; HETEROCYCLIC COMPOUNDS; HUMANS; MEDULLOBLASTOMA; PLATELET-DERIVED GROWTH FACTOR; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION; SRC-FAMILY KINASES;

ERINACEIDAE; RETROVIRIDAE;

EID: 84874478012     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-12-18     Document Type: Article

References (40)

1. von Hoff K, Rutkowski S. Medulloblastoma. Curr Treat Options Neurol 2012, 14:416-426. 10.1007/s11940-012-0183-8, 22622599.
2. Ellison DW, Kocak M, Dalton J, Megahed H, Lusher ME, Ryan SL, Zhao W, Nicholson SL, Taylor RE, Bailey S, Clifford SC. Definition of disease-risk stratification groups in childhood medulloblastoma using combined clinical, pathologic, and molecular variables. J Clin Oncol 2011, 29:1400-1407. 10.1200/JCO.2010.30.2810, 3525837, 20921458.
3. Northcott PA, Korshunov A, Witt H, Hielscher T, Eberhart CG, Mack S, Bouffet E, Clifford SC, Hawkins CE, French P, Rutka JT, Pfister S, Taylor MD. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol 2011, 29:1408-1414. 10.1200/JCO.2009.27.4324, 20823417.
4. Taylor MD, Northcott PA, Korshunov A, Remke M, Cho YJ, Clifford SC, Eberhart CG, Parsons DW, Rutkowski S, Gajjar A, Ellison DW, Lichter P, Gilbertson RJ, Pomeroy SL, Kool M, Pfister SM. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 2012, 123:465-472. 10.1007/s00401-011-0922-z, 3306779, 22134537.
5. MacDonald TJ, Brown KM, LaFleur B, Peterson K, Lawlor C, Chen Y, Packer RJ, Cogen P, Stephan DA. Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 2001, 29:143-152. 10.1038/ng731, 11544480.
6. Yuan L, Santi M, Rushing EJ, Cornelison R, Macdonald TJ. ERK activation of p21 activated kinase-1 (Pak1) is critical for medulloblastoma cell migration. Clin Exp Metastasis 2010, 7:481-491.
7. Wu X, Northcott PA, Dubuc A, Dupuy AJ, Shih DJ, Witt H, Croul S, Bouffet E, Fults DW, Eberhart CG, Garzia L, Van Meter T, Zagzag D, Jabado N, Schwartzentruber J, Majewski J, Scheetz TE, Pfister SM, Korshunov A, Li XN, Scherer SW, Cho YJ, Akagi K, MacDonald TJ, Koster J, McCabe MG, Sarver AL, Collins VP, Weiss WA, Largaespada DA, Collier LS, Taylor MD. Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature 2012, 482:529-533. 10.1038/nature10825, 3288636, 22343890.
8. Gether U, Kobilka BK. G protein-coupled receptors. II. Mechanism of agonist activation. J Biol Chem 1998, 273:17979-17982. 10.1074/jbc.273.29.17979, 9660746.
9. Gutkind JS. The pathways connecting G protein-coupled receptors to the nucleus through divergent mitogen-activated protein kinase cascades. J Biol Chem 1998, 273:1839-1842. 10.1074/jbc.273.4.1839, 9442012.
10. Janowski M, Lukomska B, Domanska-Janik K. Migratory capabilities of human umbilical cord blood-derived neural stem cells (HUCB-NSC) in vitro. Acta Neurobiol Exp (Wars) 2011, 71:24-35.
11. Dziembowska M, Tham TN, Lau P, Vitry S, Lazarini F, Dubois-Dalcq M. A role for CXCR4 signaling in survival and migration of neural and oligodendrocyte precursors. Glia 2005, 50:258-269. 10.1002/glia.20170, 15756692.
12. Vilz TO, Moepps B, Engele J, Molly S, Littman DR, Schilling K. The SDF-1/CXCR4 pathway and the development of the cerebellar system. Eur J Neurosci 2005, 22:1831-1839. 10.1111/j.1460-9568.2005.04378.x, 16262623.
13. Zhu Y, Matsumoto T, Mikami S, Nagasawa T, Murakami F. SDF1/CXCR4 signalling regulates two distinct processes of precerebellar neuronal migration and its depletion leads to abnormal pontine nuclei formation. Development 2009, 136:1919-1928. 10.1242/dev.032276, 19429788.
14. Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verástegui E, Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410:50-56. 10.1038/35065016, 11242036.
15. Busillo JM, Armando S, Sengupta R, Meucci O, Bouvier M. Site-specific phosphorylation of CXCR4 is dynamically regulated by multiple kinases and results in differential modulation of CXCR4 signaling. J Biol Chem 2010, 285:7805-7817. 10.1074/jbc.M109.091173, 2844224, 20048153.
16. Teicher BA, Fricker SP. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010, 16:2927-2931. 10.1158/1078-0432.CCR-09-2329, 20484021.
17. Cho YJ, Tsherniak A, Tamayo P, Santagata S, Ligon A, Greulich H, Berhoukim R, Amani V, Goumnerova L, Eberhart CG, Lau CC, Olson JM, Gilbertson RJ, Gajjar A, Delattre O, Kool M, Ligon K, Meyerson M, Mesirov JP, Pomeroy SL. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol 2011, 29:1424-1430. 10.1200/JCO.2010.28.5148, 3082983, 21098324.
18. Sengupta R, Dubuc A, Ward S, Yang L, Northcott P, Woerner BM, Kroll K, Luo J, Taylor MD, Wechsler-Reya RJ, Rubin JB. CXCR4 activation defines a new subgroup of Sonic Hedgehog driven medulloblastoma. Cancer Res 2012, 72:122-132. 10.1158/0008-5472.CAN-11-1701, 3520097, 22052462.
19. Pitcher JA, Freedman NJ, Lefkowitz RJ. G protein-coupled receptor kinases. Annu Rev Biochem 1998, 67:653-692. 10.1146/annurev.biochem.67.1.653, 9759500.
20. Gainetdinov RR, Premont RT, Bohn LM, Lefkowitz RJ, Caron MG. Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci 2004, 27:107-144. 10.1146/annurev.neuro.27.070203.144206, 15217328.
21. Pierce KL, Lefkowitz RJ. Classical and new roles of beta-arrestins in the regulation of G-protein-coupled receptors. Nat Rev Neurosci 2001, 2:727-733. 10.1038/35094577, 11584310.
22. Luttrell LM, Lefkowitz RJ. The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci 2002, 115:455-465.
23. Métayé T, Gibelin H, Perdrisot R, Kraimps JL. Pathophysiological roles of G-protein-coupled receptor kinases. Cell Signal 2005, 17:917-928. 10.1016/j.cellsig.2005.01.002, 15894165.
24. McCormick PJ, Segarra M, Gasperini P, Gulino AV, Tosato G. Impaired recruitment of GRK6 and beta-Arrestin 2 causes delayed internalization and desensitization of a WHIM syndrome- associated CXCR4 mutant receptor. PLoS One 2009, 4:e8102. 10.1371/journal.pone.0008102, 2779657, 19956569.
25. Fong AM, Premont RT, Richardson RM, Yu YR, Lefkowitz RJ, Patel DD. Defective lymphocyte chemotaxis in beta-arrestin2- and GRK6-deficient mice. Proc Natl Acad Sci U S A 2002, 99:7478-7483. 10.1073/pnas.112198299, 124256, 12032308.
26. Vroon A, Heijnen CJ, Raatgever R, Touw IP, Ploemacher RE, Premont RT, Kavelaars A. GRK6 deficiency is associated with enhanced CXCR4-mediated neutrophil chemotaxis in vitro and impaired responsiveness to G-CSF in vivo. J Leukoc Biol 2004, 75:698-704. 10.1189/jlb.0703320, 14704365.
27. Penela P, Ribas C, Mayor F. Mechanisms of regulation of the expression and function of G protein-coupled receptor kinases. Cell Signal 2003, 15:973-981. 10.1016/S0898-6568(03)00099-8, 14499340.
28. Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 2003, 22:337-358. 10.1023/A:1023772912750, 12884910.
29. Ke N, Wang X, Xu X, Abassi YA. The xCELLigence system for real-time and label-free monitoring of cell viability. Methods Mol Biol 2011, 740:33-43. 10.1007/978-1-61779-108-6_6, 21468966.
30. Klein RS, Rubin JB, Gibson HD, DeHaan EN, Alvarez-Hernandez X, Segal RA, Luster AD. SDF-1 alpha induces chemotaxis and enhances Sonic hedgehog-induced proliferation of cerebellar granule cells. Development 2001, 128:1971-1981.
31. Hagihara K, Zhang EE, Ke YH, Liu G, Liu JJ, Rao Y, Feng GS. Shp2 acts downstream of SDF-1alpha/CXCR4 in guiding granule cell migration during cerebellar development. Dev Biol 2009, 334:276-284. 10.1016/j.ydbio.2009.07.029, 2744846, 19635473.
32. Yang L, Jackson E, Woerner BM, Perry A, Piwnica-Worms D, Rubin JB. Blocking CXCR4-mediated cyclic AMP suppression inhibits brain tumor growth in vivo. Cancer Res 2007, 67:651-658. 10.1158/0008-5472.CAN-06-2762, 17234775.
33. Rubin JB, Kung AL, Klein RS, Chan JA, Sun Y, Schmidt K, Kieran MW, Luster AD, Segal RA. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci U S A 2003, 100:13513-13518. 10.1073/pnas.2235846100, 263845, 14595012.
34. Liu J, Liao S, Huang Y, Samuel R, Shi T, Naxerova K, Huang P, Kamoun W, Jain RK, Fukumura D, Xu L. PDGF-D improves drug delivery and efficacy via vascular normalization, but promotes lymphatic metastasis by activating CXCR4 in breast cancer. Clin Cancer Res 2011, 17:3638-3648. 10.1158/1078-0432.CCR-10-2456, 3107920, 21459800.
35. Woerner BM, Luo J, Brown KR, Jackson E, Dahiya SM, Mischel P, Benovic JL, Piwnica-Worms D, Rubin JB. Suppression of G protein-coupled Receptor Kinase 3 expression is a feature of Classical GBM that is required for maximal growth. Mol Cancer Res 2012, 10:156-166. 10.1158/1541-7786.MCR-11-0411, 3262072, 22086906.
36. Tarrant TK, Rampersad RR, Esserman D, Rothlein LR, Liu P, Premont RT, Lefkowitz RJ, Lee DM, Patel DD. Granulocyte chemotaxis and disease expression are differentially regulated by GRK subtype in an acute inflammatory arthritis model (K/BxN). Clin Immunol 2008, 129:115-122. 10.1016/j.clim.2008.06.008, 2637521, 18662895.
37. Chen Y, Lu B, Yang Q, Fearns C, Yates JR, Lee JD. Combined integrin phosphoproteomic analyses and small interfering RNA-based functional screening identify key regulators for cancer cell adhesion and migration. Cancer Res 2009, 69:3713-3720. 10.1158/0008-5472.CAN-08-2515, 2669841, 19351860.
38. Tiedemann RE, Zhu YX, Schmidt J, Yin H, Shi CX, Que Q, Basu G, Azorsa D, Perkins LM, Braggio E, Fonseca R, Bergsagel PL, Mousses S, Stewart AK. Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6. Blood 2010, 115:1594-1604. 10.1182/blood-2009-09-243980, 2830764, 19996089.
39. Wu JH, Goswami R, Kim LK, Miller WE, Peppel K, Freedman NJ. The platelet-derived growth factor receptor-beta phosphorylates and activates G protein-coupled receptor kinase-2. A mechanism for feedback inhibition. J Biol Chem 2005, 280:31027-31035. 10.1074/jbc.M501473200, 15994317.
40. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4:249-264. 10.1093/biostatistics/4.2.249, 12925520.